Protalix BioTherapeutics, Inc. - Common Shares (PLX)

CUSIP: 74365A309

Q3 2025 13F Holders as of 30 Sep 2025

Holder snapshot 7 signals
Share change
+2,010,323
Put/Call ratio
400%
SEC-reported price per share
$2.22
Number of holders
76
Value change
+$4,618,112
Number of buys
32
Open additional details 1 more signal available
Number of sells
24
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
79,957,519

Security key

74365A309

Report period

Q3 2025

Institutions

76

Top holders

10

Ownership snapshot

Top reported holders of PLX - Protalix BioTherapeutics, Inc. - Common Shares (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Dexcel Pharma Technologie...
Disclosed value leader
Dexcel Pharma Technologie...
Comparable rows
0/15
Latest evidence
30 Jun 2025
3/4/5 13F Highest disclosed value: $5,128,613 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Dexcel Pharma Technologies Ltd. has the largest disclosed position value at $5.13M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Dexcel Pharma Technologies Ltd.'s linked filing trail.
Disclosed position value Top 5
Dexcel Pharma Technologies Ltd. $5.13M
BlackRock, Inc. $4.99M
RENAISSANCE TECHNOLOGIES LLC $2.39M
NORTHERN TRUST CORP $1.6M
GEODE CAPITAL MANAGEMENT, LLC $1.22M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Dexcel Pharma Technologies Ltd.
3/4/5
10%+ Owner
—
denominator unverified
$5,128,613
3,637,314 shares
— 02 Jun 2021
BlackRock, Inc.
13F
Company
13F
—
denominator unverified
$4,987,113
3,369,670 shares
— 30 Jun 2025
RENAISSANCE TECHNOLOGIES LLC
13F
Company
13F
—
denominator unverified
$2,390,204
1,615,003 shares
— 30 Jun 2025
NORTHERN TRUST CORP
13F
Company
13F
—
denominator unverified
$1,597,990
1,079,723 shares
— 30 Jun 2025
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
13F
—
denominator unverified
$1,222,972
826,333 shares
— 30 Jun 2025
Eyal Rubin
3/4/5
Sr. VP and CFO
—
denominator unverified
$931,882
660,909 shares
— 23 Sep 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
76
Shares
13,927,352
Rows available
76
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders
62
Q3 2025 holders
76
Holder diff
14
Investor Q2 2025 Shares Q3 2025 Shares Share Diff Share Chg % Q2 2025 value Q3 2025 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .